Institut Gustave Roussy IGR

Villejuif 94805 Cedex

4 studies enrolling now · 9 studies all time

What they study most

Advanced Solid Tumor, Bladder Cancer, Carcinoma of Unknown Primary, Carcinoma, Non-Small-Cell Lung, Cervical Cancer, Cervical Squamous Cell Carcinoma, Colorectal Cancer, Esophageal Cancer, HER2 Amplification, HER2 Gene Mutation, HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer

Studies at this site

• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors — Recruiting now
• A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors — Recruiting now
• First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer — Recruiting now
• Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors — Recruiting now
• A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment — Running, not enrolling
• ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer — Running, not enrolling
• OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure — Stopped early
• Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary — Completed
• MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma — Completed